Drug intelligence / Profile preview

PC-SPES

Development stage
Discontinued
Lead developer
BotanicLab
Administration
Oral
01

Overview

**PC-SPES** is a discontinued, patented combination dietary supplement composed of eight herbal ingredients: baikal skullcap (Scutellaria baicalensis), licorice (Glycyrrhiza glabra or uralensis), reishi mushroom (Ganoderma lucidum), isatis (Isatis indigotica), ginseng (Panax ginseng or Panax pseudoginseng var. notoginseng), chrysanthemum flowers (Dendranthema morifolium), dong ling cao (Isodon rubescens), and saw palmetto (Serenoa repens)[5][7]. It was marketed for prostate health and investigated as a complementary and alternative therapy for prostate cancer, particularly hormone-resistant forms[1][3][6]. It showed in vitro anti-proliferative and pro-apoptotic effects in both androgen-sensitive and -insensitive prostate cancer cells, likely mediated through estrogenic/phytoestrogenic activity; however, later analyses found undisclosed pharmaceutical adulterants, notably diethylstilbestrol (DES), which is itself an estrogenic drug used for prostate cancer treatment[1][7][8]. The observed clinical responses (PSA decline and tumor control) in studies were attributed primarily to these contaminants. PC-SPES was withdrawn from the market in 2002 due to these safety and labeling issues[1][5][7][8].

Brand names
PC-SPESPC-CARE
Other names
Ponicidin
02

Targets

ESR1 (ERα)

Beyond the preview

Go deeper on PC-SPES.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PC-SPES.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call